Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988317 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCMAPTPKM | |
| SCHEMBL9683498 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCMAPTPKM | |
| SCHEMBL30142964 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL595640 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CC | |
| SCHEMBL30553087 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL12987462 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL13011624 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL595642 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CC | |
| SCHEMBL1296411 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL595641 | 0.92 | PPM1B (0.47) | PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| US-5128359-A | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation | LABORATOIRES UPSA (FR) | 1992-07-07 | — | — | US | disclosed |
| US-5124336-A | Cardiovascular disorders | LABORATOIRES UPSA (FR) | 1992-06-23 | — | — | US | disclosed |
| US-5021443-A | Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present | LABORATOIRES UPSA (FR) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | PPM1B 1470/4885PTPN1 457/4885PPP1CC 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.